Profile data is unavailable for this security.
About the company
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.
- Revenue in USD (TTM)116.88m
- Net income in USD-25.09m
- Incorporated1996
- Employees147.00
- LocationRigel Pharmaceuticals Inc611 GATEWAY BOULEVARD, SUITE 900SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 624-1100
- Fax+1 (650) 624-1101
- Websitehttps://www.rigel.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mediwound Ltd | 18.69m | -6.72m | 182.91m | 100.00 | -- | 5.62 | -- | 9.79 | -0.768 | -0.768 | 2.07 | 3.43 | 0.3209 | 6.28 | 2.87 | 186,860.00 | -11.53 | -24.48 | -14.35 | -32.92 | 19.15 | 43.27 | -35.94 | -38.43 | 4.33 | -- | 0.1674 | -- | -29.48 | 40.60 | 65.73 | -- | 64.66 | -- |
| Kodiak Sciences Inc | 0.00 | -260.49m | 185.45m | 111.00 | -- | 0.6974 | -- | -- | -4.97 | -4.97 | 0.00 | 5.06 | 0.00 | -- | -- | 0.00 | -45.46 | -31.73 | -49.53 | -33.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.97 | -- | 134.76 | -- |
| X4 Pharmaceuticals Inc | 0.00 | -101.17m | 185.57m | 93.00 | -- | 3.62 | -- | -- | -0.6026 | -0.6026 | 0.00 | 0.3052 | 0.00 | -- | -- | 0.00 | -66.81 | -61.53 | -78.53 | -69.20 | -- | -- | -- | -13,288.93 | -- | -- | 0.5164 | -- | -- | -- | -4.93 | -- | 12.03 | -- |
| Cardiff Oncology Inc | 488.00k | -41.47m | 189.13m | 31.00 | -- | 2.71 | -- | 387.55 | -0.9281 | -0.9281 | 0.0109 | 1.56 | 0.0049 | -- | 0.9216 | 15,741.94 | -41.90 | -31.24 | -46.15 | -33.56 | -- | -- | -8,492.01 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
| Outlook Therapeutics Inc | 0.00 | -51.50m | 189.54m | 24.00 | -- | -- | -- | -- | -3.99 | -3.99 | 0.00 | -1.87 | 0.00 | -- | -- | 0.00 | -122.07 | -214.69 | -441.62 | -1,843.48 | -- | -- | -- | -3,043.92 | -- | -- | 3.00 | -- | -- | -- | 10.70 | -- | -- | -- |
| Rigel Pharmaceuticals Inc | 116.88m | -25.09m | 191.19m | 147.00 | -- | -- | -- | 1.64 | -0.1444 | -0.1444 | 0.6717 | -0.1638 | 0.9295 | 0.9713 | 3.30 | 795,115.60 | -19.95 | -28.82 | -37.72 | -47.26 | 93.92 | 97.88 | -21.47 | -35.76 | 1.76 | -4.45 | 1.93 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
| Atossa Therapeutics Inc | 0.00 | -30.09m | 191.72m | 10.00 | -- | 2.11 | -- | -- | -0.2386 | -0.2386 | 0.00 | 0.7264 | 0.00 | -- | -- | 0.00 | -27.39 | -29.97 | -28.80 | -32.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.62 | -- | -33.90 | -- |
| Generation Bio Co | 5.90m | -126.61m | 193.48m | 174.00 | -- | 0.9485 | -- | 32.77 | -1.97 | -1.97 | 0.0916 | 3.07 | 0.0157 | -- | 2.71 | 33,931.04 | -33.72 | -36.96 | -36.60 | -39.21 | -- | -- | -2,144.51 | -8,879.44 | -- | -- | 0.00 | -- | -- | 177.31 | 7.34 | -- | 19.61 | -- |
| Acumen Pharmaceuticals Inc | 0.00 | -52.37m | 195.26m | 51.00 | -- | 0.705 | -- | -- | -1.08 | -1.08 | 0.00 | 4.61 | 0.00 | -- | -- | 0.00 | -20.67 | -- | -21.56 | -- | -- | -- | -- | -- | -- | -- | 0.103 | -- | -- | -- | -22.20 | -- | -- | -- |
| Lifecore Biomedical Inc | 103.27m | -64.24m | 196.72m | 459.00 | -- | -- | -- | 1.90 | -2.12 | -3.29 | 3.43 | 1.16 | 0.391 | 1.96 | 3.07 | 224,986.90 | -24.32 | -5.67 | -41.13 | -8.07 | 27.10 | 21.91 | -62.20 | -11.90 | 1.35 | -1.05 | 0.7495 | -- | -7.19 | -27.74 | -315.07 | -- | -8.55 | -- |
| Omeros Corp | 0.00 | -174.92m | 197.01m | 198.00 | -- | -- | -- | -- | -2.79 | -1.88 | 0.00 | -0.4087 | 0.00 | -- | -- | 0.00 | -36.09 | -55.51 | -44.88 | -70.10 | -- | -- | -- | -- | -- | -5.33 | 1.08 | -- | -- | -- | 3.91 | -- | -5.56 | -- |
| Trevi Therapeutics Inc | 0.00 | -29.07m | 197.23m | 25.00 | -- | 2.37 | -- | -- | -0.2934 | -0.2934 | 0.00 | 1.21 | 0.00 | -- | -- | 0.00 | -27.37 | -47.39 | -30.09 | -54.41 | -- | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | 0.2984 | -- | -2.81 | -- |
| CervoMed Inc | 7.14m | -2.17m | 199.49m | 8.00 | -- | 18.59 | -- | 27.92 | -0.6282 | -0.6282 | 2.07 | 1.30 | 0.4382 | -- | -- | 893,108.80 | -13.32 | -53.67 | -15.74 | -58.89 | -- | -- | -30.40 | -949.54 | -- | -- | 0.00 | -- | -- | -- | 86.07 | -- | -- | -- |
| Zevra Therapeutics Inc | 27.46m | -46.05m | 199.76m | 65.00 | -- | 3.09 | -- | 7.27 | -1.29 | -1.29 | 0.7746 | 1.49 | 0.1909 | -- | 2.14 | 422,476.90 | -32.02 | -32.11 | -45.61 | -39.89 | 45.22 | -- | -167.69 | -128.42 | -- | -- | 0.4058 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
Data as of May 02 2024. Currency figures normalised to Rigel Pharmaceuticals Inc's reporting currency: US Dollar USD
45.29%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 31 Dec 2023 | 17.10m | 9.75% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 14.41m | 8.22% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 12.87m | 7.34% |
| Soleus Capital Management LP (Investment Management)as of 31 Dec 2023 | 9.44m | 5.38% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 8.65m | 4.94% |
| Acadian Asset Management LLCas of 31 Dec 2023 | 4.62m | 2.64% |
| Geode Capital Management LLCas of 31 Dec 2023 | 3.69m | 2.11% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 3.58m | 2.04% |
| Jacobs Levy Equity Management, Inc.as of 31 Dec 2023 | 2.68m | 1.53% |
| Teachers Advisors LLCas of 31 Dec 2023 | 2.37m | 1.35% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
